NF 340Selective P2Y11 antagonist CAS# 202982-98-7 |
- Tubastatin A HCl
Catalog No.:BCC3877
CAS No.:1310693-92-5
- Entinostat (MS-275,SNDX-275)
Catalog No.:BCC3595
CAS No.:209783-80-2
- M344
Catalog No.:BCC2162
CAS No.:251456-60-7
- Panobinostat (LBH589)
Catalog No.:BCC3601
CAS No.:404950-80-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 202982-98-7 | SDF | Download SDF |
PubChem ID | 90488883 | Appearance | Powder |
Formula | C37H26N4Na4O15S4 | M.Wt | 986.84 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 20 mM in water | ||
Chemical Name | tetrasodium;4-[[3-[[5-[(3,7-disulfonatonaphthalen-1-yl)carbamoyl]-2-methylphenyl]carbamoylamino]-4-methylbenzoyl]amino]naphthalene-2,6-disulfonate | ||
SMILES | CC1=C(C=C(C=C1)C(=O)NC2=C3C=C(C=CC3=CC(=C2)S(=O)(=O)[O-])S(=O)(=O)[O-])NC(=O)NC4=C(C=CC(=C4)C(=O)NC5=C6C=C(C=CC6=CC(=C5)S(=O)(=O)[O-])S(=O)(=O)[O-])C.[Na+].[Na+].[Na+].[Na+] | ||
Standard InChIKey | SJMHXBFWMZYDBY-UHFFFAOYSA-J | ||
Standard InChI | InChI=1S/C37H30N4O15S4.4Na/c1-19-3-5-23(35(42)38-33-17-27(59(51,52)53)11-21-7-9-25(15-29(21)33)57(45,46)47)13-31(19)40-37(44)41-32-14-24(6-4-20(32)2)36(43)39-34-18-28(60(54,55)56)12-22-8-10-26(16-30(22)34)58(48,49)50;;;;/h3-18H,1-2H3,(H,38,42)(H,39,43)(H2,40,41,44)(H,45,46,47)(H,48,49,50)(H,51,52,53)(H,54,55,56);;;;/q;4*+1/p-4 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | P2Y11 antagonist; exhibits 520-fold selectivity for P2Y11 over P2Y1, P2Y2, P2Y4, P2Y6 and P2Y12 receptors. Displays competitive antagonism against ATPγS (pIC50 values are 6.43 and 7.14 in Ca2+ and cAMP assays respectively). |
NF 340 Dilution Calculator
NF 340 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.0133 mL | 5.0667 mL | 10.1334 mL | 20.2667 mL | 25.3334 mL |
5 mM | 0.2027 mL | 1.0133 mL | 2.0267 mL | 4.0533 mL | 5.0667 mL |
10 mM | 0.1013 mL | 0.5067 mL | 1.0133 mL | 2.0267 mL | 2.5333 mL |
50 mM | 0.0203 mL | 0.1013 mL | 0.2027 mL | 0.4053 mL | 0.5067 mL |
100 mM | 0.0101 mL | 0.0507 mL | 0.1013 mL | 0.2027 mL | 0.2533 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Conantokin-R
Catalog No.:BCC5980
CAS No.:202925-60-8
- glucagon receptor antagonists 2
Catalog No.:BCC1594
CAS No.:202917-18-8
- glucagon receptor antagonists 3
Catalog No.:BCC1595
CAS No.:202917-17-7
- 7-Benzyloxyindole
Catalog No.:BCC8778
CAS No.:20289-27-4
- 4-Benzyloxyindole
Catalog No.:BCC8700
CAS No.:20289-26-3
- 8-Hydroxy-3,5,7,3',4',5'-hexamethoxyflavone
Catalog No.:BCN1506
CAS No.:202846-95-5
- Rosmarinic acid
Catalog No.:BCN5893
CAS No.:20283-92-5
- Safinamide Mesylate
Catalog No.:BCC2320
CAS No.:202825-46-5
- Ralfinamide mesylate
Catalog No.:BCC7844
CAS No.:202825-45-4
- BMS 191011
Catalog No.:BCC7448
CAS No.:202821-81-6
- Licoagrochalcone A
Catalog No.:BCC8197
CAS No.:202815-28-9
- Orexin B (mouse)
Catalog No.:BCC5766
CAS No.:202801-92-1
- NF 279
Catalog No.:BCC6964
CAS No.:202983-32-2
- Aporheine
Catalog No.:BCN4802
CAS No.:2030-53-7
- Clofazimine
Catalog No.:BCC4651
CAS No.:2030-63-9
- Saponarin
Catalog No.:BCN2280
CAS No.:20310-89-8
- Solamargine
Catalog No.:BCN2305
CAS No.:20311-51-7
- Procyanidin B1
Catalog No.:BCN6314
CAS No.:20315-25-7
- Tiliroside
Catalog No.:BCN4889
CAS No.:20316-62-5
- Solamarine
Catalog No.:BCN3806
CAS No.:20318-30-3
- 3,5-Diacetamido-4-methylbenzoic acid
Catalog No.:BCN1505
CAS No.:6633-37-0
- 3,4,5-Trimethoxy-trans-cinnamic acid
Catalog No.:BCN3423
CAS No.:20329-98-0
- 3,4-Dimethoxyphenol
Catalog No.:BCN4890
CAS No.:2033-89-8
- H-D-Arg-NH2.2HCl
Catalog No.:BCC2870
CAS No.:203308-91-2
MicroRNA-340 Induces Apoptosis and Inhibits Metastasis of Ovarian Cancer Cells by Inactivation of NF-x03BA;B1.[Pubmed:27160777]
Cell Physiol Biochem. 2016;38(5):1915-27.
AIMS: Aberrant expression of microRNA-340 (miR-340) has been frequently reported in some cancers excluding ovarian cancer (OC). The role and its molecular mechanism of miR-340 in OC have not been reported. METHODS: Real-time PCR was performed to detect the expression of miR-340 in OC cell lines. MiR-340 mimic and negative control were transfected into OC cells and the effects of miR-340 on the cell proliferation, cell cycle, apoptosis and metastasis were investigated by Brdu-ELISA assay, flow cytometry, qRT-PCR, Transwell and ELISA assays. Furthermore, protein level of NF-x03BA;B1 was measured by Western blotting. Meanwhile, luciferase assays were performed to validate NF-x03BA;B1 as miR-340 target in OC cells. RESULTS: In this study, we explored the effects of miR-340 overexpression on apoptosis, invasion and EMT in OC cells. The mRNA level of miR-340 in OC cell lines and tissues was evidently reduced. The miR-340 mimic was transiently transfected into OC cells using Lipofectamine 2000 reagent. Subsequently, the Brdu-ELISA results showed that introduction of miR-340 inhibited cell proliferation. Our data also demonstrated that miR-340 mimic arrested cell cycle progression and promoted apoptosis of OC cells. In addition, miR-340 overexpression could also inhibit invasion and EMT of OC cells. qRT-PCR were used to determined the expressions of matrix metalloproteinase-2 and -9 (MMP-2 and -9) in OC cells. Next, we found that NF-x03BA;B1 expression was evidently reduced by up-regulation of miR-340. Bioinformatics analysis predicted that the NF-x03BA;B1 was a potential target gene of miR-340. Luciferase reporter assay further confirmed that miR-340 could directly target the 3' UTR of NF-x03BA;B1. Moreover, overexpression of NF-x03BA;B1 in OC cells transfected with miR-340 mimic partially reversed the inhibitory of miR-340 mimic. CONCLUSION: miR-340 induced cell apoptosis and inhibited metastasis in OC cells by down-regulation of NF-x03BA;B1.
NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-car bonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells.[Pubmed:19815812]
J Pharmacol Exp Ther. 2010 Jan;332(1):238-47.
The G protein-coupled P2Y(11) receptor is involved in immune system modulation. In-depth physiological evaluation is hampered, however, by a lack of selective and potent ligands. By screening a library of sulfonic and phosphonic acid derivatives at P2Y(11) receptors recombinantly expressed in human 1321N1 astrocytoma cells (calcium and cAMP assays), the selective non-nucleotide P2Y(11) agonist NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)carb onylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] was identified. NF546 had a pEC(50) of 6.27 and is relatively selective for P2Y(11) over P2Y(1), P2Y(2), P2Y(4), P2Y(6), P2Y(12), P2X(1), P2X(2), and P2X(2)-X(3). Adenosine-5'-O-(3-thio)triphosphate (ATPgammaS), a nonhydrolyzable analog of the physiological P2Y(11) agonist ATP, and NF546 use a common binding site as suggested by molecular modeling studies and their competitive behavior toward the nanomolar potency antagonist NF340 [4,4'-(carbonylbis(imino-3,1-(4-methyl-phenylene)carbonylimino))bis(naphthalene-2 ,6-disulfonic acid) tetrasodium salt] in Schild analysis. The pA(2) of NF340 was 8.02 against ATPgammaS and 8.04 against NF546 (calcium assays). NF546 was further tested for P2Y(11)-mediated effects in monocyte-derived dendritic cells. Similarly to ATPgammaS, NF546 led to thrombospondin-1 secretion and inhibition of lipopolysaccharide-stimulated interleukin-12 release, whereas NF340 inhibited these effects. Further, for the first time, it was shown that ATPgammaS or NF546 stimulation promotes interleukin 8 (IL-8) release from dendritic cells, which could be inhibited by NF340. In conclusion, we have described the first selective, non-nucleotide agonist NF546 for P2Y(11) receptors in both recombinant and physiological expression systems and could show a P2Y(11)-stimulated IL-8 release, further supporting the immunomodulatory role of P2Y(11) receptors.